Bhinder B, Gilvary C, Madhukar NS, Elemento O.
2021.
Artificial Intelligence in Cancer Research and Precision Medicine.. Cancer Discov. 11(4):900-915.
Croker JA, Patel R, Campbell KS, Barton-Baxter M, Wallet S, Firestein GS, Kimberly RP, Elemento O.
2021.
Building biorepositories in the midst of a pandemic.. J Clin Transl Sci. 5(1):e92.
Bruno NE, Nwachukwu JC, Srinivasan S, Nettles CC, Izard T, Jin Z, Nowak J, Cameron MD, Boregowda SV, Phinney DG et al..
2021.
Chemical systems biology reveals mechanisms of glucocorticoid receptor signaling.. Nat Chem Biol. 17(3):307-316.
Khosravi P, Lysandrou M, Eljalby M, Li Q, Kazemi E, Zisimopoulos P, Sigaras A, Brendel M, Barnes J, Ricketts C et al..
2021.
A Deep Learning Approach to Diagnostic Classification of Prostate Cancer Using Pathology-Radiology Fusion.. J Magn Reson Imaging. 54(2):462-471.
Montrose DC, Saha S, Foronda M, McNally EM, Chen J, Zhou XKathy, Ha T, Krumsiek J, Buyukozkan M, Verma A et al..
2021.
Exogenous and Endogenous Sources of Serine Contribute to Colon Cancer Metabolism, Growth, and Resistance to 5-Fluorouracil.. Cancer Res. 81(9):2275-2288.
Wolujewicz P, Aguiar-Pulido V, AbdelAleem A, Nair V, Thareja G, Suhre K, Shaw GM, Finnell RH, Elemento O, M Ross E.
2021.
Genome-wide investigation identifies a rare copy-number variant burden associated with human spina bifida.. Genet Med. 23(7):1211-1218.
Yusufova N, Kloetgen A, Teater M, Osunsade A, Camarillo JM, Chin CR, Doane AS, Venters BJ, Portillo-Ledesma S, Conway J et al..
2021.
Histone H1 loss drives lymphoma by disrupting 3D chromatin architecture.. Nature. 589(7841):299-305.
Marderstein AR, Davenport ER, Kulm S, Van Hout CV, Elemento O, Clark AG.
2021.
Leveraging phenotypic variability to identify genetic interactions in human phenotypes.. Am J Hum Genet. 108(1):49-67.
Altorki NK, McGraw TE, Borczuk AC, Saxena A, Port JL, Stiles BM, Lee BE, Sanfilippo NJ, Scheff RJ, Pua BB et al..
2021.
Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial.. Lancet Oncol. 22(6):824-835.